Biopharmaceuticals

#Biopharmaceuticals #Covid-19

Noorik Biopharmaceuticals to develop treatment for severe Covid-19 

Noorik Biopharmaceuticals, a clinical-stage biopharmaceutical company repurposing micro-dose ambrisentan for the treatment of kidney, liver, and respiratory diseases, signed a contract with the Federal Government of Switzerland to develop ambrisentan as a treatment for patients with severe Covid-19.   Why?  The investment, under the Federal Funding Programme for Covid-19 Medicines initiative, will enable… Read More

#Covid-19 #News

#Biopharmaceuticals #Heart disease

Sweet talk: “sugar soap” reverses blocked arteries 

Australian biopharmaceutical company Cholrem have produced CAVADEX (Beta-Cyclodextrin), a product which removes cholesterol from damaged and narrowed arteries after a few months of treatment, leading to increased blood flow.  Context Atherosclerosis, also known as heart disease, is reportedly the western world’s number one killer of people. This disease results… Read More

#News #Trending News

#Biopharmaceuticals #Biotechnology #Clinical trials #Covid-19 #Podcast

Clinical trials and the growing importance of technology: Podcast 

The latest sponsored DDW Sitting Down With podcast features Lisa Moneymaker and Paul O’Donohoe of Medidata and they talk to us about decentralised clinical trials. Medidata technology has helped to bring Covid-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering. Read More

#News

#Biopharmaceuticals #Biotechnology #Clinical trials #Covid-19 #Podcast #Sitting Down With

Clinical trials and the growing importance of technology

The latest sponsored DDW Sitting Down With podcast features Lisa Moneymaker and Paul O’Donohoe of Medidata and they talk to us about decentralised clinical trials. Medidata technology has helped to bring Covid-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering. Read More

#Podcasts

#Biopharmaceuticals #Drug development #Drug discovery #Immunology / Virology & Vaccines #In vivo

Agreement to develop vaccines against cancer and infectious diseases 

Nykode Therapeutics (formerly Vaccibody) has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialisation of potential new vaccines for cancer and infectious diseases.  What is the structure of the agreement?  The agreement includes five programmes, three within cancer and two within infectious diseases. Read More

#News

#AI #Biopharmaceuticals #Lab automation #Machine learning #Pharmacovigilance

AE reporting turnarounds and the translation issue 

Listen to this article on the DDW Podcast:   The workload in pharmacovigilance (PV) is soaring and as new vaccines and medications enter the market, it’s crucial to track adverse events (AE). As AE reports still have to be filed within 24 hours, Kathleen O’Brien of Amplexor Life Sciences lays out… Read More

#Editor's Choice #Exclusive Content #News #Regulatory

#Antibodies #Antibody libraries #Biologics #Biopharmaceuticals #DNA #Drug discovery #Drug targets #Screening

Newly launched antibody libraries put hard-to-drug targets within reach

Target class-specific libraries mean you need to screen less to identify high-quality antibodies. Aaron Sato, Chief Scientific Officer at Twist Bioscience, elaborates. Antibody developers are increasingly utilising antibody libraries to derive high-quality, drug-like biologics. However, only a few general-purpose libraries have been commercially available for drug discovery. As a result,… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Antivirals #Biologics #Biopharmaceuticals #Collaboration #Covid-19 #Laboratory data

This week in drug discovery (1-5 November) 

News round-up by DDW’s Megan Thomas for 1-5 November DDW’s Megan Thomas has selected five stories which showcase the international scope of the drug discovery industry in terms of research, innovation, collaboration and development. 1. New consortium to boost Covid-19 vaccine production in South Africa The Medicines Patent… Read More

#News #Trending News

#Biopharmaceuticals #Drug delivery #Drug development

Abcam acquires BioVision and expands kit 

Abcam has completed a $340m strategic acquisition of BioVision and doubled the footprint of its immunoassay kit R&D and manufacturing facility in Eugene, Oregon. This enhanced capacity is another component of Abcam’s growth in the US, which the company says will enable it to support the research and biopharma… Read More

#News

#Biopharmaceuticals #Pharmaceuticals

COP26: Biopharmaceutical industry actions to tackle climate change 

Ahead of COP26, which began on October 31 in Glasgow and runs until November 12, the Association of the British Pharmaceutical Industry (ABPI) led a joint statement from the pharmaceutical industry alongside other global associations.   Organisations included in the statement were: The European Federation of Pharmaceutical Industries… Read More

#News

#AI #Biopharmaceuticals #ELRIG #Public health

Shifting the biopharmaceutical landscape with AI 

Valo Health is a technology company built to transform drug discovery and development using human-centric data and artificial intelligence-powered compute. VP of Integrated Research, Guido Lanza talks to DDW in its Drug Discovery 2021 supplement about how Valo Health is re-inventing and innovating to overcome the fragmented, outdated… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Biopharmaceuticals #Life sciences #Regulatory

Ex-MHRA scientist leads powerhouse trio’s new biopharma excellence brand 

PharmaLex Group has announced the launch of a new service line, Biopharma Excellence, and the appointment of ex-MHRA scientific lead Dr Christian Schneider as its Chief Medical Officer.   Biopharma Excellence is a fusion of three scientific organisations, PharmaLex, ERA Consulting and Biopharma Excellence, under the PharmaLex brand. The new service line combines… Read More

#News #Regulatory

#Biopharmaceuticals #Covid-19

IDWeek 2021 will showcase scientific progress in infectious diseases

AstraZeneca will present data across its Covid-19 and respiratory syncytial virus (RSV) pipeline as three late-breaking oral presentations at the 10th Annual IDWeek Virtual Conference, September 29 to October 3, 2021, illustrating its commitment to advancing innovative science in infectious diseases.  The presentations include AZD7442 long-acting antibody combination… Read More

#News

#Biopharmaceuticals #Clinical research #Drug development #Therapeutics

Antibody-mediated therapies: meeting the challenges in R&D

By Amanda Turner, Senior Product Manager for Custom Antibody Products at Bio-Rad and Laura Moriarty, Senior Marketing Manager at Bio-Rad The global market for therapeutic antibodies represents a huge and ever-expanding opportunity for pharmaceutical developers, with the market for monoclonal antibody therapies alone being estimated to reach $300 billion… Read More

#Editor's Choice #Exclusive Content #News

#Biopharmaceuticals #Covid-19 #GlobalData

Covid-19 shapes Indian pharma deals landscape

India has a rapidly growing pharmaceutical market that, being the third largest pharmaceutical industry in the world by volume, holds a prominent place in global health. Over the last decade, the Indian pharmaceutical market has seen increasing domestic and foreign investment. While the overall number of deals fluctuated only… Read More

#Covid-19 #News #Trends & Analysis

#Biopharmaceuticals #Cell culture

Batch-to-batch consistency: premium grade bioactive proteins

From basic to translational research and clinical applications, cell culture is an essential technique that underpins the generation of promising cell and gene therapies. Since the quality of cytokines and growth factors can significantly influence the properties and function of cultured cells, these bioactive proteins must be produced to the highest standards… Read More

#Intelligence #Resources